Optimizing dosimetry imaging in high-dose radioimmunotherapy using the novel, anti-CD45 re-induction and targeted conditioning agent iodine (131)I apamistamab [Iomab-B] in patients 55 years or older with active, relapsed or refractory acute myeloid leukemia (SIERRA phase III trial) Meeting Abstract
| Authors: | Pandit-Taskar, N.; Passalaqua, S.; Wiseman, G.; Avril, N.; Yap, W.; Chen, M. K.; Wagner, R.; Natwa, M.; Chasen, B.; Lamonica, D.; Konerth, S.; Fisher, D.; Safavi, F.; Berger, M.; Reddy, V.; Griffeth, L. |
| Abstract Title: | Optimizing dosimetry imaging in high-dose radioimmunotherapy using the novel, anti-CD45 re-induction and targeted conditioning agent iodine (131)I apamistamab [Iomab-B] in patients 55 years or older with active, relapsed or refractory acute myeloid leukemia (SIERRA phase III trial) |
| Meeting Title: | 2019 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) |
| Journal Title: | Journal of Nuclear Medicine |
| Volume: | 60 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2019 Jun 22-25 |
| Meeting Location: | Anaheim, CA |
| ISSN: | 0161-5505 |
| Publisher: | Society of Nuclear Medicine |
| Date Published: | 2019-05-01 |
| Language: | English |
| ACCESSION: | WOS:000473116800432 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 433 -- Source: Wos |
MSK Authors
-
342Pandit-Taskar